Class 07 · Regenerative & tissue repair · Synthetic gastric pentadecapeptide · cytoprotection signal

BPC-157the body-protection compound · cytoprotective signal

A synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. In animal studies it accelerates the healing of tendon, ligament, muscle, gut, and nerve tissue — largely by growing new blood vessels and switching on repair programs in injured cells. It is striking in the lab and almost untested in people: as of 2026 there are only three small human pilot studies (combined n=30), none randomized or controlled. It is not approved as a drug in any country and is banned in sport by WADA. Everything below the cosmetic-grade evidence line is a hypothesis built on rodent data and clinic practice patterns — not validated prescribing.

Stable gastric pentadecapeptide (GEPPPGKPADDAGLV, MW ~1419 Da), a partial sequence of the Body Protection Compound isolated from gastric juice. Acts through a VEGFR2–Akt–eNOS angiogenic cascade, FAK–paxillin tendon-fibroblast signaling, growth-hormone-receptor upregulation, bidirectional nitric-oxide modulation, and broad neurotransmitter-system effects — almost entirely in rodent models. A 2022 ADME study established a short plasma half-life (<30 min, intact peptide) yet effects persist weeks-to-months — the "plasma/effect disconnect". No completed, peer-reviewed randomized human efficacy trial exists for any indication. All human dose ladders are extrapolations.

BPC-157 (CAS 137525-51-0, C₆₂H₉₈N₁₆O₂₂, MW ~1419 Da, PubChem CID 9941957, DrugBank DB11882) is a pleiotropic cytoprotective signal rather than a single-receptor ligand. [³H]-labelled ADME (He et al. 2022) — rat IV t½ 15.2 min, dog IV 5.27 min; undetectable at 4 h; rapid endopeptidase degradation to small fragments → free proline (86.65% of plasma radioactivity by 1 h) → amino-acid pool; IM bioavailability 14–19% (rat), 45–51% (dog). The evidence base is dominated by a single group (Sikiric et al., University of Zagreb; >100 preclinical papers) with independent mechanistic replication for VEGFR2 (Hsieh 2017/2020, Taiwan), tendon FAK-paxillin / GHR (Chang 2011/2014, Taiwan), and safety (Xu 2020, AFMU — no LD, no teratogenicity, no genotoxicity). Overall GRADE for any clinical indication: VERY LOW.

3 studies Total human pilots · combined n=30 · none RCT

<30 min Plasma half-life · intact peptide (preclinical)

>100 Preclinical studies · Zagreb-group dominant

15 AA Pentadecapeptide · GEPPPGKPADDAGLV · ~1419 Da

Status

Unapproved · investigational · off 503A Cat-2 (Apr 2026)

Open dose calculator →

Routes

SC (local / systemic) · IM · oral · IA · topical

Originator

Sikiric · Univ. Zagreb · 1993

WADA status

Prohibited · S0 (since 2022)

Molecule identity

C₆₂H₉₈N₁₆O₂₂

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val · "stable gastric pentadecapeptide" · synthetic SPPS · 1419.5 Da

ClassSynthetic cytoprotective pentadecapeptide · body-protection signal

SequenceGEPPPGKPADDAGLV · 15 residues

Molecular weight1419.5 Da · C₆₂H₉₈N₁₆O₂₂ (free base)

SynonymsPL-14736 · PL-10 · PLD-116 · Bepecin · BPC-15

Primary targetsVEGFR2 · FAK-paxillin · eNOS / NO system · GHR

Downstream effectorsAkt1 · ERK1/2 · EGR-1 · NO · collagen · multiple GFs

Plasma half-life~5–30 min (intact peptide; rat/dog, preclinical)

Effect durationWeeks–months post single dose (preclinical "switch")

RoutesSC · IM · oral · IP · IA · topical (animal + practice)

Gastric stabilityIntact >24 h in human gastric juice (in vitro)

StorageLyophilized RT/−20 °C · reconst. 2–8 °C × ~4 wk

IM bioavailability14–19% (rat) · 45–51% (dog)

PubChem / DrugBankCID 9941957 · DB11882

Primary metaboliteFree proline (M1) · 86.65% plasma radioactivity @1 h

ExcretionUrine (dominant) · bile

DiscoverySikiric · Zagreb · 1993 (BPC fragment)

01 · At a glance

Key facts & headline data.

The numbers that define BPC-157's unusual position — an enormous, mechanistically rich preclinical dataset concentrated in a single research group, an exceptionally clean animal toxicology profile, and a near-total absence of controlled human evidence. Every efficacy figure below is preclinical or practice-pattern; the regulatory and evidence-grade facts are the ones a clinician should weigh most heavily.

🧬

Origin · discovery

Gastric · 1993

Isolated and characterized in 1993 by Sikiric et al. (University of Zagreb) as a partial sequence of the cytoprotective "Body Protection Compound" present in human gastric juice. It has no sequence homology with known gut peptides. The Zagreb group has authored the majority (>100) of all published preclinical studies.

🧪

Total human evidence

n=30 · 3 pilots

As of May 2026 only three published human studies exist — intra-articular knee pain (n=16, 2021), interstitial cystitis (n=12, 2024), and IV safety/PK (n=2, 2025) — none randomized, blinded, controlled, or adequately powered. No Cochrane review or independent meta-analysis exists.

⏱️

Plasma half-life (intact)

<30 min

He et al. 2022 HPLC-based ADME: rat IV t½ 15.2 min, dog IV 5.27 min; prototype drug undetectable at 4 h. The widely-quoted 66–69 h figure refers to total radioactivity (metabolite persistence), not intact peptide. Effects nonetheless persist weeks-to-months — the plasma/effect disconnect.

🛡️

Preclinical toxicology

No LD found

Xu et al. 2020 (AFMU, most rigorous independent safety study): no minimum toxic dose and no lethal dose identified across mice, rats, rabbits, dogs; no teratogenic, genotoxic, anaphylactic, embryo-fetal, or local toxic effects; well tolerated at high doses. Long-term human safety data: completely absent.

💉

Proposed human dose

200 µg/day

A single BSA-converted figure of ~200 µg/person/day (from rat data) was used as the translation basis in the 2022 PK study — never validated in an efficacy trial. Practice-pattern human use spans 200–1,000 µg/day SC or oral, entirely extrapolated from rodent dosing (10 ng–100 µg/kg).

📋

Regulatory status (May 2026)

Unapproved · WADA S0

Not FDA-approved for any indication. Removed from FDA 503A Category 2 in April 2026; PCAC review scheduled July 2026 — not yet on the approved compounding list. Banned in sport (WADA S0) since 2022. Sold as a "research chemical" under not-for-human-consumption labeling.

02 · Mechanism of action

How a cytoprotective pentadecapeptide works.

BPC-157 doesn't act on one receptor — it nudges several repair systems at once. Its best-documented effect is angiogenesis: it tells blood vessels to sprout into injured tissue, restoring the supply line that healing depends on. It also signals tendon and gut cells to migrate, multiply, and lay down new matrix, calms inflammation, and helps normalize nitric-oxide signaling in either direction (too much or too little). Nearly all of this is shown in rats and mice, not people — so treat it as a promising mechanism story, not proven human biology.

Six mechanistically linked arms, almost all preclinical. First — a dual angiogenic cascade: VEGFR2 upregulation → PI3K → Akt → eNOS → nitric oxide, plus a Src–Caveolin-1–eNOS cytoprotective arm. Second — FAK–paxillin signaling driving tendon-fibroblast proliferation, migration, and collagen synthesis (Chang 2011, independent). Third — growth-hormone-receptor upregulation in tendon fibroblasts (Chang 2014, independent). Fourth — bidirectional nitric-oxide modulation (restores deficient NO, attenuates excess). Fifth — broad neurotransmitter-system effects (dopaminergic, serotonergic, GABAergic, glutamatergic) in rodent CNS models. Sixth — anti-inflammatory cytokine reduction with an M1→M2 macrophage shift.

BPC-157 is a pleiotropic cytoprotective signal with no canonical receptor and no established human Ki/EC50. The angiogenic axis is the most independently replicated: Hsieh 2017 (J Mol Med) confirmed VEGFR2 activation/upregulation, Hsieh 2020 (Sci Rep) confirmed Src–Caveolin-1–eNOS vasomotor modulation — both non-Zagreb (Taiwan). ERK1/2 phosphorylation is dose-dependent and causal (pharmacologic ERK blockade abolishes pro-migratory/pro-angiogenic effects); downstream c-Fos, c-Jun, EGR-1 are induced, with the EGR-1/NAB2 loop proposed as an angiogenic safety brake. The plasma/effect disconnect (t½ <30 min vs. effects persisting up to 360 days in spinal-cord-injury models) is explained as a gene-expression "switch" hypothesis — plausible but unconfirmed in humans.

🩸

Angiogenesis · VEGFR2–Akt–eNOS

The signature mechanism. BPC-157 activates a dual angiogenic cascade — a primary VEGFR2 → PI3K → Akt → eNOS → nitric-oxide arm driving endothelial proliferation and neocapillary formation, and a secondary Src–Caveolin-1–eNOS arm supporting existing vasculature. In rat hind-limb ischemia, BPC-157 increased vessel density and accelerated blood-flow recovery.

Clinical significance: Angiogenesis is the rate-limiting step in tendon, ligament, muscle, and gut repair — restoring perfusion to hypovascular injury zones (the watershed regions of tendon and the ulcerated gut mucosa) is the unifying rationale behind nearly every claimed BPC-157 indication. It is also the basis for the principal theoretical safety concern (tumor angiogenesis).

Molecular detail: Hsieh 2017 (J Mol Med, Taiwan) independently demonstrated VEGFR2 activation and upregulation associated with pro-angiogenic effects; Hsieh 2020 (Sci Rep) confirmed Src–Caveolin-1–eNOS pathway modulation of vasomotor tone. No quantified human receptor-occupancy or EC50 exists, so a mechanistic PK/PD model with target engagement (as for a biologic) cannot currently be built — the pathway is qualitatively established, quantitatively undefined.

🦵

FAK–paxillin · tendon & fibroblast repair

BPC-157 accelerates tendon and ligament repair primarily through focal adhesion kinase (FAK)–paxillin signaling — enhancing fibroblast proliferation and migration, upregulating collagen synthesis, and accelerating tendon-explant outgrowth. Chang et al. 2011 (J Appl Physiol, National Cheng Kung University, Taiwan — independent) demonstrated dose-dependent fibroblast-migration enhancement and accelerated tendon-explant outgrowth in vitro.

Clinical significance: This is the most robustly independently-replicated molecular finding and the mechanistic basis for the dominant real-world use case — soft-tissue and tendon/ligament injury. It is also the pathway behind the oncology caveat: FAK-paxillin signaling has documented roles in cancer-cell invasion and metastasis, though no animal study across 25+ years has reported tumor formation.

Molecular detail: Chang 2014 (Molecules, PMID 25462910, Taiwan) showed BPC-157 upregulates growth-hormone-receptor (GHR) expression in tendon fibroblasts, enhancing the anabolic healing response and improving tendon structure/biomechanics even when impaired by corticosteroids. Effect sizes: increased load-to-failure and higher Achilles Functional Index over 14 days vs. controls; biomechanical gains persisted through 21–72-day observation windows.

💨

Bidirectional nitric-oxide modulation

BPC-157 exhibits bidirectional NO modulation — a property the Zagreb group argues makes it uniquely cytoprotective. It counteracts both L-NAME–induced NOS inhibition (restoring NO where deficient) and L-arginine–induced NOS overactivation (attenuating NO toxicity), modulates thrombocyte function without directly affecting the coagulation cascade, and acts as a free-radical scavenger in vascular-occlusion models.

Clinical significance: This bidirectionality is framed as part of the "occlusion / occlusion-like syndrome" counteraction mechanism — the claim that BPC-157 helps re-route blood flow and stabilize endothelium after vascular compromise. It also underlies a prudent drug-interaction caution: additive effects with NO-active agents (nitrates, PDE5 inhibitors) are theoretically plausible though unstudied in humans.

Molecular detail: The NO axis intersects the angiogenic cascade at eNOS — BPC-157's normalization of NO production (rather than unidirectional stimulation or inhibition) is the proposed reason it can be both pro-angiogenic in ischemia and cytoprotective against NO-mediated oxidative injury. A theoretical excess-NO concern (eNOS upregulation → heme-thiolate enzyme inhibition, altered CYP metabolism) has been raised but was not observed in preclinical safety studies.

🫧

GI mucosal cytoprotection

Derived from a gastric protective factor, BPC-157 accelerates ulcer healing, enhances microvascular integrity, maintains epithelial tight junctions, and counteracts NSAID-induced gut damage across multiple animal models. This GI activity is the historical core of the molecule — the PL-14736 development name was used in a multicenter Phase II ulcerative-colitis enema program (Pliva, Croatia).

Clinical significance: GI / IBD-adjacent use is the second major real-world application. The PL-14736 ulcerative-colitis program is the most advanced clinical development BPC-157 has ever reached — but the Phase II RCT was presented only as a 2005 conference abstract (Gastroenterology 128:A584) and was never published as a full peer-reviewed paper, so its results cannot be independently verified.

Molecular detail: The gut-brain axis is conceptually grounded in cytoprotection theory — gut-integrity maintenance, peripheral wound healing, and CNS homeostasis are described as expressions of a single cytoprotective cascade extending "from the stomach." Stable in human gastric juice >24 h in vitro (the empirical basis for "stable gastric pentadecapeptide"), supporting the rationale for oral GI dosing despite a short systemic half-life.

🧠

Neurotransmitter-system modulation

BPC-157 does not meet classical neurotransmitter criteria but exerts broad bidirectional modulatory effects across rodent CNS models. Dopaminergic (counteracts MPTP/reserpine/haloperidol/amphetamine effects), serotonergic (antidepressant in forced-swim, anxiolytic in elevated-plus-maze), GABAergic (anticonvulsant), glutamatergic (normalizes NMDA overactivation), adrenergic, and cholinergic/NMJ stabilization.

Clinical significance: These findings underpin speculative interest in BPC-157 for neuroprotection, mood, and neuromuscular recovery — but they are essentially all from a single group, in rodents, with no human neuropsychiatric trial of any kind. The translational distance here is the largest of any BPC-157 application; clinician counseling should treat CNS claims as the least substantiated.

Molecular detail: Spinal-cord-injury models showed functional improvement and reduced spasticity maintained up to 360 days after a single treatment — the most extreme example of the plasma/effect disconnect. The proposed "biological switch" hypothesis (rapid activation of Akt1, VEGFR2, eNOS, and growth-factor gene programs triggering self-sustaining cascades) is mechanistically plausible but unconfirmed in humans, and CNS pathways have essentially no independent replication.

🛡️

Anti-inflammatory & ERK1/2 program

BPC-157 decreases pro-inflammatory cytokines (TNF-α, IL-6, IFN-γ), promotes a reparative M1→M2 macrophage phenotype shift, and lowers malondialdehyde (a lipid-peroxidation injury marker). In endothelial models it dose-dependently enhances ERK1/2 phosphorylation, increasing proliferation, migration, and vascular tube formation, with downstream c-Fos / c-Jun / EGR-1 induction.

Clinical significance: The anti-inflammatory arm supports the broad "recovery / general wellness" use case and the rationale for combining BPC-157 with other repair peptides. It is the least specific mechanism — cytokine reduction and M1→M2 shifts are shared by many regenerative agents — so it provides mechanistic plausibility rather than indication-specific evidence.

Molecular detail: Inhibitor studies establish ERK pathway causality — pharmacologic ERK blockade abolishes BPC-157's pro-migratory and pro-angiogenic effects. The EGR-1 transcription factor and its corepressor NAB2 form a regulatory feedback loop proposed to limit excessive angiogenic signaling — a putative built-in safety brake. This intersects the VEGFR2 and FAK-paxillin nodes, making ERK1/2 a convergence point for the angiogenic and tendon-repair programs.

L3 · Downstream pathway

Administration → BPC-157 → Receptor-level Targets → Gene Program → Tissue Phenotype

💉

Dose
t½ <30 min

→

⚗️

BPC-157
(15 AA)

→

🎯

VEGFR2 · FAK
eNOS · GHR

→

🏛️

Akt · ERK1/2
EGR-1 program

→

🧱

Angiogenesis +
matrix repair

→

⚖️

Anti-inflamm +
NO balance

→

🏆

Tissue healing
(persistent)

03 · Dosing protocols & models

Protocol-specific dosing architecture.

This is a speculative, hypothesis-driven dosing engine — every ladder, threshold, and titration rule below is layered on top of (1) animal dosing ranges and the single BSA-converted human estimate, and (2) current human practice-pattern ranges (200–1,000 µg/day) that are not evidence-based. No standardized, trial-validated human dose ladder exists for any BPC-157 indication as of 2026. The structure mirrors how clinicians titrate biologics and is intended as a base for protocol critique and research design — not validated prescribing. Each protocol is built to the same skeleton: starting dose, escalation cadence, dose ladder, maintenance target, cycle structure, reconstitution math, monitoring overlay, and explicit evidence grade.

Important · regulatory status & evidence ceiling BPC-157 is not FDA-approved for any human indication in any jurisdiction. It was removed from the FDA 503A Category 2 bulks list in April 2026, with a Pharmacy Compounding Advisory Committee (PCAC) review scheduled for July 2026 — it is not yet on the approved 503A compounding list and remains an unapproved drug. It is banned in sport (WADA S0) since 2022. All dose ladders, biomarker thresholds, and titration rules below carry evidence grade D (practice-pattern) or P (preclinical extrapolation) and must not be read as clinical guidelines. Use only under IRB-approved research protocols or physician-supervised informed-consent settings, with verified product source.

2026 PK note · why these dosing patterns are heuristic The intact-peptide plasma half-life is <30 minutes (rat IV 15.2 min, dog IV 5.27 min; undetectable by 4 h), yet preclinical effects persist weeks to months — up to 360 days after a single dose in spinal-cord-injury models. This plasma/effect disconnect means BPC-157 is administered as a repeated pulse signal, not titrated to a steady-state plasma level. There is no validated assay, no therapeutic range, and no meaningful trough/peak concept — attempting PK-guided dosing (e.g. drawing a "level" 24 h post-dose) is currently meaningless. Once- or twice-daily dosing reflects practice-pattern "exposure cover," not measured kinetics. Classical pharmacology would predict nominal steady state within ~4–5 half-lives (≲2–3 h) if dosed continuously — but it is not dosed continuously, and human kinetics are not measured.

Indication framing

Hamstring strain, muscle tear, sprain, acute ligament injury. Sports-medicine reviews and practice guides converge on 250–750 µg/day for 2–4 weeks, up to 1,000 µg/day for severe injury — all extrapolated from rodent musculoskeletal models, none human-validated.

Starting dose

250 µg SC once daily near the injury for <75 kg; 250 µg SC BID (500 µg/day) if ≥75 kg or higher severity. Local (peri-injury) injection is favored for the theoretical advantage of higher local concentration, supported by animal data.

Escalation cadence

Reassess at week 2. If <30% subjective pain reduction on VAS and no adverse events → increase daily total by ~250 µg (250 µg QD → 500 µg QD; 500 µg → 750 µg QD or 375 µg BID). Escalation is gated on both a response floor and a safety floor.

Dose ladder

250 µg/day → 500 µg/day → 750 µg/day → (cap) 1,000 µg/day. Do not exceed 1,000 µg/day without an explicit "experimental mode" flag — this is the upper bound of reputable clinic write-ups and ~5× the BSA-derived 200 µg/day estimate.

Maintenance / taper

After the acute window, optional 250–500 µg/day maintenance while rehab continues. Many protocols taper rather than stop abruptly.

Cycle structure

2–4 weeks for minor injury; up to 6 weeks for surgery-level injury, then a 2–4 week washout. No human data defines optimal cycle length; cycling is a conservative default.

Reconstitution & injection

Typical 5 mg vial + 2 mL bacteriostatic water → 2,500 µg/mL = 25 µg/unit (U-100). 250 µg = 10 units (0.1 mL); 500 µg = 20 units (0.2 mL). 29–31 G insulin syringe, SC, rotate sites. Roll — don't shake. Refrigerate reconstituted product 2–8 °C, use within ~4 weeks, protect from light, avoid freeze-thaw. Use the calculator below to derive exact draw volumes for any vial/dose.

Monitoring overlay (borrowed)

Baseline + week 2/4: pain VAS/NRS, LEFS (Lower Extremity Functional Scale), CK, hsCRP, and CMP/CBC for safety. MCID surrogates borrowed from ortho/sports-med (≈1–1.5 points VAS; ≈9 points LEFS) flag non-response. These are tendon/sports-med thresholds, not BPC-157 thresholds — a heuristic overlay only.

PK heuristic note

Given t½ <30 min and once-daily effective dosing in animals, BID human dosing here is purely "exposure cover" — not based on measured levels. Target internal range ≈ 3–10 µg/kg/day for adult weights, consistent with practice patterns and within an order of magnitude of preclinical dosing (10 ng–100 µg/kg/day).

⚠ Evidence & source checkpoint No human RCT has compared local vs. systemic routes, validated any dose, or established a dose–response curve for acute injury. The dominant real-world safety risk is product quality: a Drug Testing and Analysis study found ~30% of online peptides contain incorrect sequences and ~65% exceed endotoxin safety thresholds. Minimum standards for any injectable use: HPLC ≥98% purity, sterility certification, endotoxin limits, and mass-spectrometry identity confirmation.

Indication framing

Chronic tendinopathy, partial tears, enthesopathy, ligament laxity. Clinic guides converge on 250–500 µg 1–2× daily for 4–6 weeks; the FAK-paxillin/GHR tendon mechanism is the most independently-replicated rationale.

Starting dose

250 µg SC QD for mild; 250 µg BID (500 µg/day) for moderate-to-severe. Local peri-tendon injection where anatomically safe; otherwise systemic SC/IM.

Escalation cadence

Reassess at week 3 (chronic tissue responds slower than acute). If <20% improvement on a function scale (VISA-A / VISA-P for Achilles/patellar, or LEFS) and no adverse events → increase by 250 µg/day.

Dose ladder

250 µg/day → 500 µg/day → 750 µg/day → (cap) 1,000 µg/day. Higher chronic-block protocols exist anecdotally but add no efficacy data.

Maintenance target

500 µg/day through the active healing block, with optional step-down to 250 µg/day during rehab consolidation.

Cycle structure

4–6 weeks on, then a mandatory 2–4 week washout. Chronic tendinopathy often requires repeated cycles; document response cycle-to-cycle before resuming.

Reconstitution & injection

Same math as acute protocol — 5 mg vial + 2 mL BAC water → 25 µg/unit; 250 µg = 10 units, 500 µg = 20 units. For chronic use favor systemic SC (abdomen, rotate) for convenience; reserve precise peri-tendon injection for clinician administration under imaging where appropriate.

Monitoring overlay (borrowed)

Baseline + week 3/6: VISA-A/VISA-P or LEFS, pain VAS, ± ultrasound/MRI for structural tracking, CMP/CBC for safety. MCID values are from tendon-rehab trials, not BPC-157 — a heuristic overlay.

Mechanistic rationale

Chang 2014 showed GHR upregulation in tendon fibroblasts with preserved healing even under corticosteroid impairment — the strongest independent molecular basis for a tendon indication, though still in vitro / animal.

Indication framing

Ulcer / IBD-adjacent surrogate use (gastritis, NSAID-gut, functional GI complaints). The historical core indication — PL-14736 reached a Phase II ulcerative-colitis enema program, but the RCT was abstract-only (Gastroenterology 2005, 128:A584) and never fully published. Clinic/medspa protocols use 200–500 µg oral 1–2× daily for 4–8 weeks.

Starting dose

250 µg oral QD for mild symptoms; 250 µg oral BID (500 µg/day) for moderate. Oral dosing exploits in-vitro gastric stability (intact >24 h) for local mucosal effect.

Escalation cadence

Reassess at week 4 (GI mucosal turnover is slower). If no ≥30% reduction in a generic GI symptom score (borrowed from IBD symptom indices) and no adverse events → increase to 750–1,000 µg/day total.

Dose ladder

250 µg/day → 500 µg/day → 750 µg/day → (cap) 1,000 µg/day, oral. SC may be substituted/added for systemic or refractory cases.

Maintenance target

500 µg/day oral through the healing block; step down to 250 µg/day for symptom maintenance if responding.

Cycle structure

4–8 weeks on (up to 12 for refractory mucosal healing), then ≥4 weeks off. Re-evaluate endoscopically/symptomatically before resuming.

Oral formulation note

Reconstituted solution taken orally, or capsule/liquid from a verified compounder. No quantified human oral bioavailability (F%) exists — oral dosing is rationalized by gastric stability and rodent oral activity, not measured human absorption.

Monitoring overlay (borrowed)

Baseline + week 4/8: CRP, fecal calprotectin, generic GI symptom index (CDAI-style), ± endoscopic score for IBD-adjacent use, CMP/CBC for safety. Borrowed from IBD biologic trials, not validated for BPC-157.

Route rationale

For localized gut pathology, oral/intragastric concentrates drug at the target mucosa; for systemic GI or extra-intestinal involvement, SC provides systemic exposure. Animal data support both oral and systemic routes for GI indications; no head-to-head human comparison exists.

Indication framing

"General recovery / systemic support" — the weakest-evidenced use case, with no indication-specific data. Treat as opt-in "experimental wellness mode" with bright warnings. Community protocols use 200–300 µg daily, 5 days/week, 4–8 weeks.

Starting / conservative band

200–350 µg/day SC, near the BSA-derived 200 µg/day estimate and the lower end of clinic guides. Deliberately conservative because there is no defined target to titrate toward.

Escalation cadence

Generally no escalation for non-indication use — without an objective endpoint, dose-chasing is discouraged. Hold at the conservative band or discontinue if no clear subjective benefit by 4 weeks.

Dose ladder

200 µg/day → 300 µg/day (ceiling for this mode). Crossing into 500–1,000 µg/day territory should reclassify the use as injury/indication-driven with an objective endpoint, not "wellness."

Cycle structure

4–8 weeks on, 5 days/week, then a break. The 5-days-on/2-off pattern is a practice-pattern convenience, not evidence-based.

Reconstitution

5 mg vial + 2 mL BAC water → 25 µg/unit; 200 µg = 8 units, 300 µg = 12 units. Same storage/handling as other SC protocols.

Monitoring overlay

Basic labs only (CMP/CBC) at baseline and end-of-cycle. No indication-specific biomarker is meaningful here. Counsel honestly that systemic "wellness" use has the thinnest rationale of any BPC-157 application.

⚠ Lowest-evidence use case There is no indication-based evidence for "general wellness" BPC-157. This panel exists to model conservative bounds and discourage dose escalation in the absence of an objective endpoint — not to endorse the use case. Default to the conservative band, cycle, and reassess; prefer addressing a specific injury or GI target with a defined endpoint instead.

Rationale

A dedicated oral route for upper-GI / luminal targets, separated from the broader gut protocol because oral pharmacology and handling differ. Justified by >24 h stability in human gastric juice in vitro and rodent oral GI activity; human oral F% remains unquantified.

Starting dose

250 µg orally 1–2× daily, ideally on an empty stomach or per compounder guidance. "Research standard" oral ranges run 500–1,000 µg/day.

Dose ladder

250 µg/day → 500 µg/day → 1,000 µg/day. Oral ceilings run slightly higher than SC in practice patterns, on the assumption of lower bioavailability — though F% is unknown, so this is an assumption, not a correction.

Cycle structure

4–8 weeks, then ≥4 weeks off. Pair with standard GI care (PPI, dietary triggers) rather than as a replacement.

Reconstitution / dosing math

Reconstituted solution measured by insulin-syringe volume then taken orally, or pre-formulated oral product. 5 mg vial + 2 mL BAC water → 25 µg/unit; 250 µg = 0.1 mL, 500 µg = 0.2 mL. Use the calculator below for any vial/dose combination.

Monitoring overlay (borrowed)

Symptom score, CRP, ± calprotectin, CMP/CBC. Endoscopic confirmation for any ulcer/IBD-adjacent claim. Same caveat: thresholds borrowed, not BPC-157-validated.

Global dose bands · practice-pattern + PK bridge

Three daily dose tiers & weight-band interpolation.

The engine anchors every protocol to three adult daily-dose tiers. Weight bands default to a target of ≈ 3–10 µg/kg/day — consistent with practice ranges and within an order of magnitude of preclinical dosing (10 ng–100 µg/kg/day). All values are evidence grade D/P.

Band	Daily total (adult)	Rationale	Grade
Low	200–350 µg/day	Near the BSA-converted 200 µg/day estimate and the lower end of clinic guides; conservative / wellness / sensitive individuals.	P/D
Standard	400–700 µg/day	Matches typical practitioner dosing (250–500 µg 1–2×/day); the default working band for injury / GI indications.	D
High ceiling	800–1,000 µg/day	Upper bound of reputable clinic write-ups; above 1,000 µg/day flag as off-protocol "experimental mode."	D

Weight-band interpolation (speculative)

Body weight	Low band	Standard band	High ceiling	≈ µg/kg/day (std)
~55 kg (120 lb)	200 µg	400 µg	600 µg	~7 µg/kg
~68 kg (150 lb)	250 µg	500 µg	750 µg	~7 µg/kg
~82 kg (180 lb)	300 µg	600 µg	900 µg	~7 µg/kg
~91 kg (200 lb)	300–350 µg	700 µg	1,000 µg	~8 µg/kg
~105 kg (230 lb)	350 µg	700 µg	1,000 µg (cap)	~7 µg/kg

Weight bands are interpolated from clinic articles and the µg/kg/day heuristic; no formal µg/kg formula or trial basis exists. No pediatric dosing trials or structured pediatric protocols exist — pediatric use is off-protocol by default.

Titration logic · engine-ready decision rules

Escalation, hold & stop logic.

Generic heuristics mirroring how clinicians titrate biologics — clearly marked unvalidated for BPC-157. Escalation requires both a response floor (below the borrowed MCID surrogate) and a safety floor (no flags) before stepping the dose. Hard stops are non-editable and reflect regulatory/ethical caution rather than observed BPC-157 events.

Decision node	Rule template (generic — not BPC-157-validated)	Grade
Escalate	If `time_on_therapy ≥ Tmin` (2 wk acute / 3 wk chronic / 4 wk GI) AND `improvement < MCID_surrogate` (≈20–30% change on the borrowed scale) AND no safety flags → step to next higher band (+~250 µg/day).	D
De-escalate	If new mild systemic symptoms (headache, nausea, mild edema) temporally linked to a dose increase → return to prior band and shorten cycle, or stop. No BPC-specific thresholds.	D
Hold	If ALT/AST or lipase >2–3× ULN, platelets <100k, new hypertension, or any acute thrombotic/bleeding event → hold and assess. Thresholds borrowed from NSAID / biologic / hepatotoxicity-pancreatitis practice.	A/B outside BPC · D here
Permanent stop (hard)	New malignancy diagnosis or progression on therapy (theoretical pro-angiogenic / FAK-paxillin risk); pregnancy or lactation (no reproductive data); severe organ dysfunction; patient preference after disclosure. Encode as non-editable red hard-stops.	P/D

Special populations — renal, hepatic, elderly, obesity, pregnancy: no PK/PD data stratified by eGFR or Child-Pugh exists for BPC-157. Conservative default: avoid use in these groups outside IRB-approved protocols.

Biomarker scaffold · borrowed, not validated

Response & safety monitoring bundles.

No BPC-157 trial defines a biomarker-based endpoint, numeric target, or MCID. Each bundle below is imported from the standard of care for the analogous condition and explicitly flagged validated_for_BPC = false. The engine drives escalation/de-escalation off the direction of change and whether the borrowed MCID is met — not off any BPC-157-specific cut-off.

Timepoint	Labs / tests (example: acute muscle/tendon)	Interpretation (borrowed)	Validated for BPC?
Baseline	CBC, CMP (AST/ALT/ALP/bilirubin), CK, hsCRP; pain VAS; LEFS/VISA; ± imaging	Establish normal limits; high CK/CRP = severity marker, not a contraindication.	No
Week 2	CK, hsCRP, pain VAS, LEFS or function scale	MCID ≈ 1–1.5 pts VAS; ≈ 9 pts LEFS — failure to approach MCID flags non-response → escalation gate.	No
Week 4	Above + functional test (single-leg hop / strength)	Approaching pre-injury function = response; far below with no trend → consider stop / re-evaluate diagnosis.	No
GI bundle	CRP, fecal calprotectin, CDAI-style symptom index, ± endoscopic score	≥30% symptom reduction = response (borrowed from IBD biologic trials).	No
Safety (all)	CMP, CBC, lipase if symptomatic	Hold thresholds borrowed from hepatotoxicity / pancreatitis guidelines (see titration table).	No

Architecture note: store each biomarker with a source_therapy tag and a validated_for_BPC boolean (currently false across the board). Flip to true only when an actual BPC-157 trial — e.g. a future registered RCT — supports it.

Acute-injury ladder · practice-pattern · grade D/P

Visual titration: from initiation to washout.

Week 1–2 250µg/day · init SC near injury · tolerability + response floor

Week 2–3 500µg/day · step 2 If <30% VAS drop & no AE → escalate

Week 3–4 750µg/day · step 3 Standard→high band · reassess function

Week 4–6 1,000µg/day · cap High ceiling · severe injury only

Week 6–8 250–500maintenance Taper during rehab consolidation

Then Washout2–4 wk off Reassess · repeat cycle if benefit clear

L2 · Reconstitution & dose math

Reconstitution & Dose Calculator

For reference only. Not medical dosing advice. BPC-157 is dosed in micrograms (µg) — small draw volumes mean precision matters. Verify peptide purity (≥98% HPLC), sterility, endotoxin limits, identity (MS), and storage. Only use product from a licensed / verified source for any injection protocol.

Vial size (mg)

BAC water (mL)

Target dose (µg)

Syringe

Concentration

—

Draw volume
—

Units (U-100)

—

Doses per vial

—

Cadence basis

—

04 · Combination protocols

Stacking BPC-157.

BPC-157 is frequently combined with other repair peptides in the wellness/fitness world. No published controlled study has evaluated BPC-157 in combination with any other peptide in humans — every stack below is a community-derived concept based on mechanistic complementarity, not clinical-trial data. No pharmacokinetic or pharmacodynamic interaction data exist. The default engine rule is to keep each component in its mid-range band and avoid simultaneous high-end dosing of multiple agents.

BPC-157 250–500 µg/day TB-500 ~2–5 mg/week SC · cycled

The most popular regenerative stack. The mechanistic complementarity is real at the individual-compound level — BPC-157 drives VEGFR2 local angiogenesis and FAK-paxillin tendon repair, while TB-500 (a thymosin β4 fragment) sequesters G-actin to drive systemic cell migration and MMP-mediated remodeling. The receptor/mechanism profiles are distinct (local + systemic). The only human combination evidence is a retrospective intra-articular knee pilot (n=16) comparing BPC-157 alone vs. BPC-157 + TB4, with no control group and no statistical analysis. Engine default: cap BPC-157 at the "standard" band when TB-500 is ≥4–5 mg/week.

Component	Primary mechanism	Evidence
BPC-157	VEGFR2 angiogenesis · FAK-paxillin (local)	Preclinical (P)
TB-500	G-actin sequestration · migration (systemic)	Preclinical · no human RCT (P)
Combination	Local + systemic repair	1 retrospective pilot (D)

BPC-157 250–500 µg/day GHK-Cu (topical / SC) wound + remodeling

Theoretical complementarity for wound and scar remodeling — BPC-157 drives angiogenesis and early repair while GHK-Cu supports collagen/elastin synthesis and matrix remodeling in the consolidation phase. No published preclinical or human studies combine these agents. The pairing is sequential-logic-driven (angiogenic repair → matrix remodeling) rather than evidenced. Keep both at mid-range; GHK-Cu topical use carries the least systemic risk of the combination.

Component	Role	Status
BPC-157	Angiogenesis · early repair	Preclinical (P)
GHK-Cu	Collagen / elastin · remodeling	Cosmetic-approved · small clinical (B/C)
Combination	Repair → remodeling sequence	No combination data (D)

BPC-157 (oral / SC) KPV (Lys-Pro-Val) gut / anti-inflammatory

KPV — a C-terminal α-MSH tripeptide with anti-inflammatory activity targeted at intestinal mucosa — is paired with BPC-157 in community gut protocols for additive anti-inflammatory and mucosal-healing effect. No published preclinical or human studies combine these agents. Mechanistically plausible (complementary mucosal anti-inflammatory pathways) but entirely speculative; treat as exploratory and keep doses conservative.

Component	Role	Status
BPC-157	GI cytoprotection · angiogenesis	Preclinical (P)
KPV	α-MSH-derived mucosal anti-inflammatory	Preclinical (P)
Combination	Additive mucosal healing	No data (D)

BPC-157 ≤ standard band CJC-1295 / Ipamorelin GH-axis stacking

Community recovery stacks layer BPC-157's repair signal with GH-secretagogue-driven anabolism. Engine default: do not exceed the "standard" BPC-157 band if CJC/Ipamorelin are at typical doses, and add monitoring for fluid retention, blood pressure, and glucose — stacking multiple growth-repair axes may increase edema and metabolic effects. No interaction data exist; this is conservative-by-design.

Component	Mechanism	Added monitoring
BPC-157	Tissue repair · angiogenesis	Standard panel
CJC / Ipamorelin	GH/IGF-1 axis	Edema · BP · fasting glucose

Hard constraint

Contraindicated / high-caution combinations. Concurrent use with anti-angiogenic cancer therapies, anti-VEGF agents (e.g. bevacizumab), or in patients with known/active malignancy warrants extreme caution due to potential pathway interference and the theoretical pro-angiogenic / FAK-paxillin metastasis concern. If a user profile flags active malignancy, the engine should suppress all pro-angiogenic stacks — not just BPC-157 — and label the combination "discouraged." Additive caution also applies to NO-active drugs (nitrates, PDE5 inhibitors) given BPC-157's NO-system modulation. All such flags are mechanistic / pathway-based, with no human outcome data.

05 · Safety profile & contraindications

Clean in animals; almost untested in humans.

BPC-157 has a paradoxical safety picture: an exceptionally clean preclinical toxicology profile across multiple species, yet almost no systematically collected human adverse-event data. The most rigorous independent safety study (Xu 2020, AFMU) found no minimum toxic dose, no lethal dose, and no teratogenic, genotoxic, anaphylactic, or embryo-fetal effects across mice, rats, rabbits, and dogs. The three human pilots (combined n=30) reported no adverse effects — but n=30 is far too small for any safety conclusion, and no long-term human data exists at all. The FDA's September 2023 Category-2 listing cited immunogenicity, manufacturing impurities, and insufficient human data — without disclosing a specific safety signal. No dose–toxicity curve or MTD has been established in humans.

Observed / Reported AE Profile (limited human + practice-pattern)

Human pilots · no AEs reportedAcross all three published human studies (IA knee n=16, intravesical IC n=12, IV up to 20 mg n=2) no adverse effects were reported; the IV pilot showed no clinically meaningful changes in vitals, ECG, or cardiac/hepatic/renal/thyroid/metabolic labs. Reassuring but underpowered.

Injection-site reactionsMild erythema, transient stinging, or local swelling at SC sites — practice-pattern reports, generally self-limited. Rotate sites; reduce concentration if recurrent.

Mild systemic symptoms (anecdotal)Headache, transient nausea, or mild fatigue reported anecdotally early in titration; not systematically characterized. Usually self-resolves.

No organ toxicity in acute animal modelsIn rodents, BPC-157 in acute (<6 week) models showed no gross or histologic organ toxicity in liver, spleen, kidney, or other organs.

Metabolic safety pathwayDegradation to small fragments → free proline → normal amino-acid pool, consistent with general peptide-drug behavior — the mechanistic basis for the metabolic-safety argument.

Theoretical & Unresolved Risks

Pathologic angiogenesis / tumor promotionVEGFR2 upregulation and FAK-paxillin signaling (metastasis-related) raise a theoretical tumor-promotion concern. Counterpoint: no tumor formation in any animal study across 25+ years, and some anti-tumor effects observed. Unresolved without long-term human cancer surveillance.

Excess NO productioneNOS upregulation theoretically could disrupt heme-thiolate enzymes / hemoglobin assembly and alter CYP metabolism (proposed anemia / drug-metabolism risk). Not observed in preclinical safety studies — theoretical only.

Proline-metabolite toxicityProline (primary metabolite M1) → superoxide production theoretically. Not observed at therapeutic doses in preclinical safety work — very low, theoretical.

Drug interactions (unknown)No human PK drug–drug interaction studies. Caution with NO-active drugs (PDE5 inhibitors, nitrates) is prudent given NO-pathway modulation.

ImmunogenicityPeptide immunogenicity cited by FDA as a compounding concern; not reported in the limited human studies. Uncharacterized at scale.

Product quality / contamination~30% of online peptides contain incorrect sequences and ~65% exceed endotoxin safety thresholds. This is a real, substantial risk for non-pharmaceutical-grade product — likely the dominant practical hazard.

Long-term safety (absent)No >12-month human data. Absence of evidence is not evidence of safety — the single largest unknown.

Contraindication reference (precautionary)

Given the absence of human data, all contraindications are precautionary — based on theoretical mechanism and regulatory caution, not observed BPC-157 events.

Condition / factor	Risk level	Applies to	Rationale
Active or prior malignancy	Avoid	All routes	Theoretical tumor-angiogenesis / FAK-paxillin metastasis concern; no data to establish safety. Avoid outside trials.
Pregnancy	Avoid	All routes	No human embryo-fetal data; rodent studies showed no teratogenicity, but human data absent — contraindicated by absence of evidence.
Lactation	Avoid	All routes	No lactation / infant-exposure data. Avoid until lactation complete.
Concurrent anti-angiogenic / anti-VEGF therapy	Avoid	Systemic	Theoretical pharmacologic antagonism with bevacizumab and similar agents.
Concurrent NO-modulating agents (nitrates, PDE5i)	Caution	Systemic	Theoretical additive NO effect; no interaction data.
Competitive athlete / WADA testing pool	Avoid	All routes	Banned under WADA S0 (unapproved substances) since 2022 — use is a doping violation regardless of safety.
Autoimmune disease	Caution	Systemic	No data; peptide immunogenicity and unknown immune modulation argue for caution.
Severe renal or hepatic impairment	Caution	Systemic	No PK stratified by eGFR / Child-Pugh. Conservative: avoid outside IRB-approved protocols.
Pediatric use	Avoid	All routes	No pediatric dosing trials or structured protocols exist. Off-protocol by default.
Unverified "research-chemical" product	Avoid	All routes	Sequence-error and endotoxin contamination are the dominant practical risk; require HPLC ≥98%, sterility, endotoxin, and MS identity.

Suggested monitoring for BPC-157 research protocols

Baseline

CMP (LFTs, renal), CBC, ± lipase, fasting glucose, lipid panel; pregnancy test if reproductive potential; malignancy screen / history review. Indication-specific endpoint baseline: pain VAS + function scale (musculoskeletal); CRP + calprotectin + symptom index (GI); imaging where relevant.

Week 2 (acute) / Week 3–4 (chronic / GI)

Symptom and tolerability review (injection-site, headache, nausea, edema). Response check against borrowed MCID surrogate → escalation gate. Safety labs if any symptom flag.

Mid-cycle (week 4)

Repeat indication endpoint + targeted safety labs (CMP, CBC, lipase if symptomatic). Decision: continue, escalate, hold, or step back per titration logic.

End of cycle

Repeat endpoint + safety panel. Document objective and subjective outcomes for cycle-to-cycle comparison. Decision: washout, resume, modify, or discontinue.

Washout / reassess (2–4 wk post)

Confirm symptom trajectory off-drug; reassess whether a further cycle is justified by clear prior benefit.

Stop / hold criteria (hard)

New malignancy diagnosis or progression, pregnancy, severe injection-site or systemic reaction, ALT/AST or lipase >2–3× ULN, platelets <100k, new thrombotic/bleeding event, or any new diagnosis changing the risk/benefit calculus.

06 · Key studies & research program

A vast preclinical base, three small human pilots.

BPC-157's evidence base is among the most lopsided in this atlas — >100 preclinical studies (concentrated in the Zagreb group) against just three published human pilots totaling n=30, none randomized or controlled. The complete published human record, the most-cited preclinical work, the PL-14736 ulcerative-colitis program, and the publication-bias caveat are summarized below.

Human pilot · 2021

n=16

IA knee injection (Lee & Padgett); 14/16 reported significant pain relief at 6–12 mo. Retrospective, no control, mixed diagnoses, no blinding.

Human pilot · 2024

n=12

Intravesical for interstitial cystitis (Lee, Walker & Ayadi); 80–100% symptom resolution at 6 wk per GRA. Open-label, no control, not registered.

Human pilot · 2025

n=2

IV up to 20 mg (Lee & Burgess, PMID 40131143); well tolerated, plasma clearance to baseline within 24 h. No PK parameters reported.

Combined

n=30

Total human evidence to date. None randomized, blinded, controlled, or adequately powered. No registered RCT active as of May 2026.

P PK / ADME · anchor

He et al. 2022 — first rigorous independent ADME / PK

The Chinese Air Force Medical University group's [³H]-labelled study (Front. Pharmacol., PMID 36588717) established the operative intact-peptide half-life (rat IV 15.2 min, dog IV 5.27 min; undetectable at 4 h), IM bioavailability (14–19% rat, 45–51% dog), rapid endopeptidase degradation to free proline, and urine/bile excretion — the most rigorous preclinical PK dataset and the basis for the BSA-converted 200 µg/day human estimate.

PMID 36588717

P Safety · anchor

Xu et al. 2020 — preclinical safety evaluation

The most rigorous independent (AFMU, Xi'an) safety evaluation (Regul. Toxicol. Pharmacol., PMID 32334036): no minimum toxic dose and no lethal dose in mice, rats, rabbits, or dogs; no teratogenic, genotoxic, anaphylactic, or embryo-fetal effects; well tolerated at high doses across species — the foundation of the metabolic-safety argument. Acute (<6 wk) rodent models showed no gross or histologic organ toxicity.

PMID 32334036

C Mechanism · independent

Chang 2011 / 2014 — tendon FAK-paxillin & GHR (Taiwan)

Chang 2011 (J Appl Physiol, PMID 21164169) demonstrated dose-dependent fibroblast migration and accelerated tendon-explant outgrowth in vitro. Chang 2014 (Molecules, PMID 25462910) showed growth-hormone-receptor upregulation in tendon fibroblasts, improving structure/biomechanics even under corticosteroid impairment. The most robustly independently-replicated molecular findings — non-Zagreb (National Cheng Kung University).

PMID 25462910 PMID 21164169

C Clinical program · GI

PL-14736 — the ulcerative-colitis program

The most advanced clinical development BPC-157 ever reached: a Pliva (Croatia) PL-14736 enema for mild-to-moderate UC. A Phase I safety study in healthy males was reported safe (UEGW 2002, no full paper). A Phase II multicenter, randomized, double-blind, placebo-controlled study was presented only as a 2005 conference abstract (Gastroenterology 128:A584) and has never been published as a full peer-reviewed paper — its results cannot be independently verified.

Search record

C Human · IV safety

Lee & Burgess 2025 — first human IV safety/PK

Two healthy adults received IV BPC-157 up to 20 mg; well tolerated with no adverse effects and no clinically meaningful changes in vitals, ECG, or cardiac/hepatic/renal/thyroid/metabolic labs; plasma cleared to baseline within 24 h (PMID 40131143). The only human PK-relevant data — but n=2, no formal PK parameters, no comparator.

PMID 40131143

D Research program · gap

Publication bias & single-group dominance

All published BPC-157 studies report positive or beneficial effects — a pattern consistent with significant publication bias. The Zagreb group publishes with near-exclusive positive framing; no negative preclinical study has been published. The 2025 University of Utah scoping review (McGuire et al.) and the 2025 Polish review (Jozwiak et al.) both flag this as limiting the robustness of conclusions. No Cochrane review or independent meta-analysis exists.

PMID 40789979 ClinicalTrials.gov

GRADE summary

Across every indication — tendon/ligament, muscle, GI/UC, wound, bone, interstitial cystitis, CNS/neuroprotection, cardiovascular, and performance — the overall evidence grade is VERY LOW. The base is characterized by near-exclusive reliance on rodent models, near-complete concentration in a single research group, only three published human pilots (n=30 combined), the absence of any blinded/controlled/adequately-powered human trial, no independent systematic review or meta-analysis, and likely publication bias toward positive findings. The IV safety pilot (n=2, up to 20 mg, no AEs) is promising but far too small for any safety conclusion. This is precisely why the dosing engine above is framed as a speculative hypothesis layer, not a guideline.

BPC-157 vs. the repair-peptide family

Parameter	BPC-157	TB-500 (Tβ4 fragment)	GHK-Cu (copper tripeptide)
Structure	15-AA synthetic pentadecapeptide; gastric origin	7-AA fragment (Ac-LKKTETQ) of thymosin β4 (43 AA)	Tripeptide (Gly-His-Lys) · Cu²⁺ complex
Primary mechanism	VEGFR2-Akt-eNOS angiogenesis; FAK-paxillin; NO; neurotransmitter modulation	G-actin sequestration → cell migration; VEGF/MMP; systemic remodeling	Epigenetic gene modulation (~31% genome); collagen/elastin/GAG; copper shuttle
Target scope	Local (tendon, gut) + systemic	Systemic (broad cell migration)	Skin, connective tissue (primarily topical)
Human clinical evidence	3 uncontrolled pilots (n=30 total)	Parent Tβ4: Phase I/II cardiac/corneal; fragment itself: no human trials	One RCT-method study (n=21) + cosmetic/wound studies
Independent replication	Limited but present (Taiwan, Korea, China)	Very limited for fragment	More independent replication than BPC-157
Safety profile	No LD in animals; only 30 humans studied	Parent Tβ4 acceptable in limited trials; fragment: no human data	Endogenous since-1973; extensive topical use; acceptable
WADA status	Prohibited (S0) since 2022	Prohibited (S0)	Non-injectable not prohibited; injectable under review
FDA compounding	Off Cat-2 Apr 2026; PCAC Jul 2026	Off Cat-2 Apr 2026; PCAC Jul 2026	Cosmetic-approved (INCI); injectable under PCAC review
Typical use case	Tendon / ligament / gut / CNS recovery	Systemic tissue repair · anti-inflammatory	Skin wound healing · anti-aging

07 · Compare & contrast

Adjacent peptides.

08 · Evidence & references

Every claim, graded and sourced.

A · RCT / meta-analysis

B · Large cohort / consistent trial set

C · Small trial / mechanistic

P · Preclinical / animal

D · Expert / textbook / regulatory

Explore the ATLAS index

BPC-157the body-protection compound · cytoprotective signal

Key facts & headline data.

How a cytoprotective pentadecapeptide works.

Angiogenesis · VEGFR2–Akt–eNOS

FAK–paxillin · tendon & fibroblast repair

Bidirectional nitric-oxide modulation

GI mucosal cytoprotection

Neurotransmitter-system modulation

Anti-inflammatory & ERK1/2 program

Protocol-specific dosing architecture.

Three daily dose tiers & weight-band interpolation.

Weight-band interpolation (speculative)

Escalation, hold & stop logic.

Response & safety monitoring bundles.

Visual titration: from initiation to washout.

Reconstitution & Dose Calculator

Stacking BPC-157.

Clean in animals; almost untested in humans.

Contraindication reference (precautionary)

Suggested monitoring for BPC-157 research protocols

A vast preclinical base, three small human pilots.

He et al. 2022 — first rigorous independent ADME / PK

Xu et al. 2020 — preclinical safety evaluation

Chang 2011 / 2014 — tendon FAK-paxillin & GHR (Taiwan)

PL-14736 — the ulcerative-colitis program

Lee & Burgess 2025 — first human IV safety/PK

Publication bias & single-group dominance

BPC-157 vs. the repair-peptide family

Adjacent peptides.

Every claim, graded and sourced.

More Repair / Immune peptides & tools.